关键词： VistaGen 干细胞
2013年4月12日讯 /生物谷BIOON/ --位于旧金山的制药公司VistaGen宣布公司已经筹集了3600万美元用于支持公司的干细胞研究。公司是通过将股份出售给Bergamo Acquisition公司的形式来获得该笔资金。
公司CEO Shawn K. Singh表示在过去的十五年中，公司投入了超过5000万美元来研究利用干细胞技术治疗人类心脏病等疾病。（生物谷Bioon.com）
详细英文报道：
South San Francisco-based VistaGen Therapeutics says it's raised $36 million, selling shares to Bergamo Acquisition for 50 cents apiece. The biotech says it will use the cash to "accelerate and expand its stem cell technology-based drug rescue programs." "Since our inception nearly 15 years ago, we have carefully deployed more than $53 million, including over $15 million from grant awards and collaboration revenue, to successfully develop innovative stem cell technology and bioassay systems capable of bringing clinically relevant human heart and liver biology to the front end of the drug development process," stated CEO Shawn K. Singh.
